Citadel Advisors’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-67,786
Closed -$38K 15534
2024
Q2
$41.9K Sell
67,786
-96,407
-59% -$81.5K ﹤0.01% 11953
2024
Q1
$422K Sell
164,193
-140,379
-46% -$343K ﹤0.01% 8750
2023
Q4
$621K Sell
304,572
-48,167
-14% -$87.9K ﹤0.01% 7634
2023
Q3
$607K Sell
352,739
-87,609
-20% -$156K ﹤0.01% 7637
2023
Q2
$859K Sell
440,348
-117,417
-21% -$275K ﹤0.01% 6776
2023
Q1
$1.55M Buy
557,765
+169,950
+44% +$486K ﹤0.01% 5853
2022
Q4
$1.34M Sell
387,815
-57,795
-13% -$165K ﹤0.01% 6260
2022
Q3
$1.15M Sell
445,610
-59,377
-12% -$189K ﹤0.01% 6695
2022
Q2
$1.22M Sell
504,987
-134,509
-21% -$353K ﹤0.01% 6560
2022
Q1
$2.63M Buy
639,496
+292,415
+84% +$1.55M ﹤0.01% 5468
2021
Q4
$4.46M Buy
347,081
+133,961
+63% +$1.48M ﹤0.01% 4525
2021
Q3
$2.3M Buy
213,120
+179,619
+536% +$1.63M ﹤0.01% 6000
2021
Q2
$306K Sell
33,501
-416,695
-93% -$3.85M ﹤0.01% 11213
2021
Q1
$4.25M Buy
+450,196
New +$6.2M ﹤0.01% 4635
2020
Q3
Sell
-77,750
Closed -$517K 10895
2020
Q2
$517K Sell
77,750
-23,070
-23% -$155K ﹤0.01% 7012
2020
Q1
$587K Buy
100,820
+5,719
+6% +$48K ﹤0.01% 6201
2019
Q4
$853K Buy
95,101
+4,725
+5% +$39.4K ﹤0.01% 5888
2019
Q3
$780K Sell
90,376
-56,840
-39% -$574K ﹤0.01% 6018
2019
Q2
$1.64M Buy
147,216
+74,395
+102% +$851K ﹤0.01% 4857
2019
Q1
$969K Buy
72,821
+60,450
+489% +$808K ﹤0.01% 5649
2018
Q4
$191K Sell
12,371
-51,935
-81% -$991K ﹤0.01% 7900
2018
Q3
$916K Buy
+64,306
New +$916K ﹤0.01% 5699

Other funds holding GRTS

Citadel Advisors's GRTS Position: Q3 2024 in Review

Citadel Advisors sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q3 2024, closing a stake of 67,786 shares — an estimated $38K sold.

Citadel Advisors first reported a position in GRTS in Q3 2018 and held it in 22 quarters. The position peaked at $4.46M in Q4 2021. 56 funds tracked by Wall St. Rank hold GRTS as of Q3 2024.

  • Citadel Advisors reported no remaining Gritstone bio, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 67,786 Gritstone bio, Inc. Common Stock shares in Q3 2024, an estimated $38K.
  • Citadel Advisors first reported a position in Gritstone bio, Inc. Common Stock in Q3 2018 and held it in 22 quarters.
  • Citadel Advisors's Gritstone bio, Inc. Common Stock position peaked at $4.46M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.